JP2013525819A - 予想される検体関係を評価することによるポイント・オブ・ケア検査結果の検証法 - Google Patents
予想される検体関係を評価することによるポイント・オブ・ケア検査結果の検証法 Download PDFInfo
- Publication number
- JP2013525819A JP2013525819A JP2013509302A JP2013509302A JP2013525819A JP 2013525819 A JP2013525819 A JP 2013525819A JP 2013509302 A JP2013509302 A JP 2013509302A JP 2013509302 A JP2013509302 A JP 2013509302A JP 2013525819 A JP2013525819 A JP 2013525819A
- Authority
- JP
- Japan
- Prior art keywords
- concentration
- potassium
- measured
- chloride
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 49
- 238000012123 point-of-care testing Methods 0.000 title description 6
- 238000012795 verification Methods 0.000 title description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims abstract description 92
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 82
- 239000011734 sodium Substances 0.000 claims abstract description 82
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 81
- 238000009826 distribution Methods 0.000 claims abstract description 74
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims abstract description 70
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims abstract description 66
- 239000011591 potassium Substances 0.000 claims abstract description 66
- 229910052700 potassium Inorganic materials 0.000 claims abstract description 66
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 50
- 239000011575 calcium Substances 0.000 claims abstract description 50
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 50
- 108010088751 Albumins Proteins 0.000 claims abstract description 40
- 102000009027 Albumins Human genes 0.000 claims abstract description 40
- 229940109239 creatinine Drugs 0.000 claims abstract description 35
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 31
- 239000011777 magnesium Substances 0.000 claims abstract description 31
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 31
- 150000001450 anions Chemical class 0.000 claims abstract description 14
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000011574 phosphorus Substances 0.000 claims abstract description 12
- 229910052698 phosphorus Inorganic materials 0.000 claims abstract description 12
- 229910019142 PO4 Inorganic materials 0.000 claims abstract description 10
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims abstract description 10
- 239000010452 phosphate Substances 0.000 claims abstract description 10
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 9
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 9
- 238000012360 testing method Methods 0.000 claims description 31
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 claims description 20
- 108010010234 HDL Lipoproteins Proteins 0.000 claims description 19
- 238000009533 lab test Methods 0.000 claims description 10
- 238000008050 Total Bilirubin Reagent Methods 0.000 claims description 9
- 108010028554 LDL Cholesterol Proteins 0.000 claims description 6
- 108010023302 HDL Cholesterol Proteins 0.000 claims description 4
- 239000012491 analyte Substances 0.000 abstract description 78
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 27
- 108010082126 Alanine transaminase Proteins 0.000 description 27
- 239000000523 sample Substances 0.000 description 26
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 24
- 238000005259 measurement Methods 0.000 description 22
- 102000015779 HDL Lipoproteins Human genes 0.000 description 17
- 108010007622 LDL Lipoproteins Proteins 0.000 description 16
- 102000007330 LDL Lipoproteins Human genes 0.000 description 16
- 235000012000 cholesterol Nutrition 0.000 description 12
- 102000004420 Creatine Kinase Human genes 0.000 description 11
- 108010042126 Creatine kinase Proteins 0.000 description 11
- 238000012937 correction Methods 0.000 description 11
- 230000000875 corresponding effect Effects 0.000 description 11
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 10
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 8
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 239000013610 patient sample Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 6
- 230000006870 function Effects 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 238000008789 Direct Bilirubin Methods 0.000 description 4
- 230000009103 reabsorption Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 206010067125 Liver injury Diseases 0.000 description 3
- 208000001647 Renal Insufficiency Diseases 0.000 description 3
- 239000012482 calibration solution Substances 0.000 description 3
- 238000007418 data mining Methods 0.000 description 3
- 231100000234 hepatic damage Toxicity 0.000 description 3
- 201000006370 kidney failure Diseases 0.000 description 3
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000008818 liver damage Effects 0.000 description 3
- 238000000611 regression analysis Methods 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 208000007848 Alcoholism Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 201000007930 alcohol dependence Diseases 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000008085 renal dysfunction Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- BCHLTFOMLWCYIS-UHFFFAOYSA-N 4-amino-5-chloro-n-[2-(diethylamino)ethyl]-2-methoxybenzamide;n-(4-hydroxyphenyl)acetamide;hydrochloride Chemical compound Cl.CC(=O)NC1=CC=C(O)C=C1.CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC BCHLTFOMLWCYIS-UHFFFAOYSA-N 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N aldosterone group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C=O)C(=O)CO PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 1
- 229930182480 glucuronide Natural products 0.000 description 1
- 150000008134 glucuronides Chemical class 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 231100000857 poor renal function Toxicity 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/20—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Primary Health Care (AREA)
- Data Mining & Analysis (AREA)
- Biomedical Technology (AREA)
- Databases & Information Systems (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33215410P | 2010-05-06 | 2010-05-06 | |
| US61/332,154 | 2010-05-06 | ||
| US37866810P | 2010-08-31 | 2010-08-31 | |
| US61/378,668 | 2010-08-31 | ||
| PCT/US2011/035583 WO2011140483A2 (en) | 2010-05-06 | 2011-05-06 | Validation of point-of-care test results by assessment of expected analyte relationships |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013525819A true JP2013525819A (ja) | 2013-06-20 |
| JP2013525819A5 JP2013525819A5 (https=) | 2014-06-19 |
Family
ID=44902517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013509302A Pending JP2013525819A (ja) | 2010-05-06 | 2011-05-06 | 予想される検体関係を評価することによるポイント・オブ・ケア検査結果の検証法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20110276342A1 (https=) |
| EP (1) | EP2567339A4 (https=) |
| JP (1) | JP2013525819A (https=) |
| KR (1) | KR20130105301A (https=) |
| CA (1) | CA2798456A1 (https=) |
| WO (1) | WO2011140483A2 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020080491A1 (ja) * | 2018-10-17 | 2020-04-23 | 株式会社 資生堂 | 血液中のクレアチニン量に基づく腎機能検査結果の妥当性を検定する方法 |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8645306B2 (en) | 2010-07-02 | 2014-02-04 | Idexx Laboratories, Inc. | Automated calibration method and system for a diagnostic analyzer |
| US9151769B2 (en) * | 2010-07-02 | 2015-10-06 | Idexx Laboratories, Inc. | Automated calibration method and system for a diagnostic analyzer |
| US11676730B2 (en) | 2011-12-16 | 2023-06-13 | Etiometry Inc. | System and methods for transitioning patient care from signal based monitoring to risk based monitoring |
| US20130231949A1 (en) | 2011-12-16 | 2013-09-05 | Dimitar V. Baronov | Systems and methods for transitioning patient care from signal-based monitoring to risk-based monitoring |
| EP2685264B1 (en) * | 2012-07-13 | 2020-12-02 | Idexx Laboratories, Inc. | Automated calibration method and system for a diagnostic analyzer |
| US20140222463A1 (en) * | 2013-01-31 | 2014-08-07 | Abbott Cardiovascular Systems Inc. | Enhanced monitoring |
| US11036779B2 (en) * | 2018-04-23 | 2021-06-15 | Verso Biosciences, Inc. | Data analytics systems and methods |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08147396A (ja) * | 1994-09-22 | 1996-06-07 | A & T:Kk | 臨床検査分析装置 |
| JP2009247688A (ja) * | 2008-04-08 | 2009-10-29 | Kochi Univ | 臨床検査データ解析支援装置、臨床検査データ解析支援方法及びそのプログラム |
| JP2010181276A (ja) * | 2009-02-05 | 2010-08-19 | Oita Univ | 臨床検査値の管理装置、管理方法及び管理プログラム |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK409188D0 (da) * | 1988-07-21 | 1988-07-21 | Radiometer As | Fremgangsmaade til maaling af en karakteristik i et fluidum |
| US6015667A (en) * | 1996-06-03 | 2000-01-18 | The Perkin-Emer Corporation | Multicomponent analysis method including the determination of a statistical confidence interval |
| JP2001331581A (ja) * | 2000-05-22 | 2001-11-30 | Yusuke Tsukamoto | 自動診断システム、自動診断方法、治療法自動決定システム、治療法自動決定方法及び記録媒体 |
| IL152740A0 (en) * | 2000-05-31 | 2003-06-24 | Fasttrack Systems Inc | Clinical trials management system and method |
| WO2003019184A1 (en) * | 2001-08-24 | 2003-03-06 | Bio-Rad Laboratories, Inc. | Biometric quality control process |
| US20060160074A1 (en) * | 2001-12-27 | 2006-07-20 | Third Wave Technologies, Inc. | Pharmacogenetic DME detection assay methods and kits |
| US7177767B2 (en) * | 2002-10-18 | 2007-02-13 | Abaxis, Inc. | Systems and methods for the detection of short and long samples |
| ES2334671T3 (es) * | 2004-08-13 | 2010-03-15 | Egomedical Technologies Ag | Sistema de ensayo de analitos para determinar la concentracion de un analito en un fluido fisiologico o acuoso. |
| US8112232B2 (en) * | 2007-02-02 | 2012-02-07 | Beckman Coulter, Inc. | System and method for autoverifying laboratory test results |
| US20110046919A1 (en) * | 2009-03-02 | 2011-02-24 | Juliesta Elaine Sylvester | Method for accurate measurement of enzyme activities |
-
2011
- 2011-05-06 EP EP20110778441 patent/EP2567339A4/en not_active Withdrawn
- 2011-05-06 US US13/102,394 patent/US20110276342A1/en not_active Abandoned
- 2011-05-06 CA CA2798456A patent/CA2798456A1/en not_active Abandoned
- 2011-05-06 JP JP2013509302A patent/JP2013525819A/ja active Pending
- 2011-05-06 WO PCT/US2011/035583 patent/WO2011140483A2/en not_active Ceased
- 2011-05-06 KR KR1020127031906A patent/KR20130105301A/ko not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08147396A (ja) * | 1994-09-22 | 1996-06-07 | A & T:Kk | 臨床検査分析装置 |
| JP2009247688A (ja) * | 2008-04-08 | 2009-10-29 | Kochi Univ | 臨床検査データ解析支援装置、臨床検査データ解析支援方法及びそのプログラム |
| JP2010181276A (ja) * | 2009-02-05 | 2010-08-19 | Oita Univ | 臨床検査値の管理装置、管理方法及び管理プログラム |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020080491A1 (ja) * | 2018-10-17 | 2020-04-23 | 株式会社 資生堂 | 血液中のクレアチニン量に基づく腎機能検査結果の妥当性を検定する方法 |
| JPWO2020080491A1 (ja) * | 2018-10-17 | 2021-09-09 | Kagami株式会社 | 血液中のクレアチニン量に基づく腎機能検査結果の妥当性を検定する方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2798456A1 (en) | 2011-11-10 |
| KR20130105301A (ko) | 2013-09-25 |
| WO2011140483A3 (en) | 2012-04-05 |
| US20110276342A1 (en) | 2011-11-10 |
| EP2567339A4 (en) | 2013-10-23 |
| EP2567339A2 (en) | 2013-03-13 |
| WO2011140483A2 (en) | 2011-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013525819A (ja) | 予想される検体関係を評価することによるポイント・オブ・ケア検査結果の検証法 | |
| Allardet-Servent et al. | Point-of-care versus central laboratory measurements of hemoglobin, hematocrit, glucose, bicarbonate and electrolytes: a prospective observational study in critically ill patients | |
| Timbrell | The role and limitations of the reference interval within clinical chemistry and its reliability for disease detection | |
| US7177767B2 (en) | Systems and methods for the detection of short and long samples | |
| Shephard | Point-of-care testing and creatinine measurement | |
| Wyatt et al. | Estimating kidney function in HIV-infected adults in Kenya: comparison to a direct measure of glomerular filtration rate by iohexol clearance | |
| Kosack et al. | Evaluation of the Nova StatSensor® XpressTM creatinine point-of-care handheld analyzer | |
| Shemesh et al. | Agreement between laboratory results and on-site pathology testing using Bayer DCA2000+ and Cholestech LDX point-of-care methods in remote Australian Aboriginal communities | |
| Nah et al. | Evaluation of bilirubin interference and accuracy of six creatinine assays compared with isotope dilution–liquid chromatography mass spectrometry | |
| EP3971910B1 (en) | Method for predicting markers which are characteristic for at least one medical sample and /or for a patient | |
| Andersen et al. | Detecting reduced renal function in children: comparison of GFR-models and serum markers | |
| Kang et al. | Performance evaluation of presepsin using a Sysmex HISCL‐5000 analyzer and determination of reference interval | |
| Mondejar et al. | Utility of icteric index in clinical laboratories: more than a preanalytical indicator | |
| Law et al. | Misclassification of calcium status in end‐stage kidney disease using albumin‐adjusted calcium levels | |
| Aurora et al. | Suppression tumorigenicity 2 (ST2) turbidimetric immunoassay compared to enzyme-linked immunosorbent assay in predicting survival in heart failure patients with reduced ejection fraction | |
| Ercan | Comparison of test results obtained from lithium heparin gel tubes and serum gel tubes | |
| Coetzee et al. | The role of point-of-care blood testing for ketones in the diagnosis of diabetic ketoacidosis | |
| Lee et al. | Performance evaluation of the i‐Smart 300E cartridge for point‐of‐care electrolyte measurement in serum and plasma | |
| Cigula Kurajica et al. | Determination of cystatin C reference interval for children in Croatia | |
| US6925391B1 (en) | Methods and apparatus for detecting artifactual output from a chemical analyzer | |
| Mulya Harahap et al. | Comparative analysis of serum magnesium ion levels using three measurement methods: spectrophotometry, atomic absorption spectrophotometry, and inductively coupled plasma with optical emission spectrophotometry | |
| Bowen et al. | Blood collection device components: issues, innovations, and recommendations for clinical laboratories and manufacturers—a narrative review | |
| Tel-Karthaus et al. | Instrument dependent erroneous sodium measurements in hypoproteinemic critically ill patients are causing significant misclassification of dysnatremias. | |
| Londeree et al. | Bodily fluid analysis of non-serum samples using point-of-care testing with iSTAT and Piccolo analyzers versus a fixed hospital chemistry analytical platform | |
| Zaidi et al. | Assessment of Total Laboratory Errors in Clinical Chemistry Laboratory: Experience at a Tertiary Care Hospital |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140425 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140425 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20141127 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141201 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150227 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150729 |